At a Glance
AbbVie is a global biopharmaceutical company that spun off from Abbott Laboratories in 2013. While primarily known as a pharmaceutical company with blockbuster drugs like Humira, AbbVie also operates AbbVie Ventures, its strategic investment arm. The company focuses on investments that align with its core therapeutic areas including immunology, oncology, neuroscience, and eye care. AbbVie Ventures typically makes strategic investments in biotechnology companies developing innovative therapies, diagnostic tools, and enabling technologies. The firm leverages AbbVie's deep scientific expertise, regulatory knowledge, and global commercial capabilities to support portfolio companies. Notable investments have included partnerships with companies developing next-generation immunotherapies and precision medicine platforms. Led by CEO Richard Gonzalez and supported by a strong R&D organization, AbbVie combines its pharmaceutical expertise with venture investing to identify and nurture breakthrough medical innovations.
“Corporate venture arm investing in biotechnology and pharmaceutical companies that align with AbbVie's therapeutic areas.”
AbbVie primarily invests at the Pre-Seed, Seed, Series A, Series B+ stages. This means they focus on companies that are at the earliest idea or prototype phase.
AbbVie is headquartered in North Chicago, IL. Many of their portfolio companies are also based in this region, though they invest across geographies.
AbbVie focuses on investments in Aerospace & Defense, Digital Health, Other, Consumer, Fintech. Their portfolio reflects deep expertise and networks within these sectors.
AbbVie's typical investment check size ranges from $. to $.. Actual amounts may vary based on the stage, sector, and specific opportunity.
